Abstracts tagged "Adalimumab"

Abstract Number: 595 • 2015 ACR/ARHP Annual Meeting
Discovery of Serum Protein Biomarkers of Response to Adalimumab in Rheumatoid Arthritis and Their Relationship to Biomarkers of Response to Infliximab
Ignacio Ortea¹, Bernd Roschitzki², Eva Tomero³, Juan G. Ovalles-Bonilla⁴, Javier Lopez-Longo⁵, Inmaculada de la Torre⁵, Isidoro Gonzalez-Alvaro⁶, Juan J Gomez-Reino⁷ and Antonio Gonzalez⁸, ¹Maimónides Health Research Institute (IMIBIC), Cordoba, Spain, ²Functional Genomics Center Zurich, University and ETH Zurich, Zurich, Switzerland, ³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁴Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Gregorio Marañon Hospital, Madrid, Spain, ⁶Hospital Univ. de La Princesa, IIS Princesa, Madrid, Spain, ⁷Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁸Laboratorio Investigacion 10 and Rheumatology Unit, Instituto Investigacion Sanitaria- Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
Background/Purpose: Biomarkers of response to treatment in rheumatoid arthritis (RA) are sorely needed given the large inter-individual variability in efficacy of the available drugs. However,…
Abstract Number: 598 • 2015 ACR/ARHP Annual Meeting
Economic Impact of Decreasing Adalimumab and Etanercept Doses and Drug Monitoring in Patients with Rheumatoid Arthritis in Clinical Remission: Preliminary Study from a Local Biologics Unit
José Rosas¹, Francisca Llinares-Tello², José Miguel Senabre¹, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Xabier Barber³, Ana Pons⁴, Catalina Cano⁴, Marisa Lorente⁵ and Juan Molina⁶, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ²Clinical Analysis, Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain, ³Centro de Investigación Operativa, Miguel Hernández University, Elche, Spain, ⁴Hospital Marina Baixa, Nursing, Villajoyosa, Spain, ⁵Marina Baixa Hospital, Nursing, Villajoyosa, Spain, ⁶Hospital Marina Baixa, Clinical Analysis, Villajoyosa, Spain
Background/Purpose: To evaluate the economic impact of adalimumab (ADL) and etanercept (ETN) dose reduction (by decreasing treatment frequency) and drug monitoring in patients with rheumatoid…
Abstract Number: 612 • 2015 ACR/ARHP Annual Meeting
Thromboembolic Events Are Not Associated with Anti-Adalimumab Antibodies
Gerd Burmester¹, Cem Gabay², Dilek Arikan³, Anabela Cardoso⁴, Jasmina Kalabic³, Nathan Pfeifer³, Nupun A. Varothai³, Stefan Florentinus⁵ and Josef S. Smolen⁶, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Rheumatology, Geneva University Hospital, Geneva, Switzerland, ³AbbVie, North Chicago, IL, ⁴Torre Oriente, AbbVie, Lisboa, Portugal, ⁵AbbVie Inc., North Chicago, IL, ⁶Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: Treatment of rheumatoid arthritis (RA) with anti-Tumor Necrosis Factor (TNF) such as adalimumab may result in some patients (pts) developing anti-adalimumab antibodies (AAA). Findings…
Abstract Number: 651 • 2015 ACR/ARHP Annual Meeting
The Prediction of Long-Term Minimal Disease Activity and Its Benefits in Patients with Psoriatic Arthritis
Philip J. Mease¹, Arthur Kavanaugh², Laura C Coates³, Iain McInnes⁴, Maja Hojnik⁵, Ying Zhang⁶, Jaclyn K. Anderson⁶, Alex Dorr⁶ and Dafna Gladman⁷, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²University of California San Diego, La Jolla, CA, ³Leeds Teaching Hospitals Trust, Leeds, United Kingdom, ⁴University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom, ⁵AbbVie, Ljubljana, Slovenia, ⁶AbbVie, North Chicago, IL, ⁷Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Minimal disease activity (MDA)1 is a clinically meaningful and comprehensive treatment target for psoriatic arthritis (PsA). The purpose was to determine if baseline (BL)…
Abstract Number: 2036 • 2015 ACR/ARHP Annual Meeting
Infliximab Versus Adalimumab in Severe Uveitis: Multicenter Study from the French Uveitis Network
Hélène Vallet¹, Pascal Sève², Lucie Biard³, Elodie Feurer⁴, Sophie Rivière⁵, Philip Bielfeld⁶, Laurent Perard⁷, Boris Bienvenu⁸, Sébastien Abad⁹, Aude Rigolet¹⁰, Alban Deroux¹¹, Antoinette Perlat¹², Damien Sène¹³, Isabelle Marie¹⁴, Emmanuel Heron¹⁵, Eric Hachulla¹⁶, Olivier Fain¹⁷, Gaëlle Clavel¹⁸, Jean Sibilia¹⁹, Nathalie Tieulié²⁰, Yoland Schoindre²¹, Jean Baptiste Fraison²², Guillaume Moulis²³, Thomas Papo²⁴, Gilles Blaison²⁵, Julie Gueudry²⁶, Olivier Lidove²⁷, Phuc LE Hoang²⁸, Catherine Chapelon²⁹, Mathieu Resche Regon³⁰, Patrice Cacoub¹³, Bahram Bodaghi²⁸ and David Saadoun³¹, ¹Internal medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Internal medicine, CHU Lyon, Lyon, France, ³Biostatistics, Saint-Louis Hospital, Paris, France, ⁴Internal Medicine, Hôpital de la Croix Rousse, Lyon, France, ⁵service de médecine interne A,, CHU de Montpellier, Montpellier Cedex 5, France, ⁶CHU de Dijon, Dijon, France, ⁷Hôpital Edouard Herriot, Lyon, France, ⁸Internal Medicine, Hospital Caen, Caen, France, ⁹Hôpital Avicenne, Bobigny, France, ¹⁰Médecine Interne 1, Hôpital Pitié-Salpêtrière, Paris, France, ¹¹Internal Medicine, CHU Grenoble, Grenoble, France, ¹²Internal medicine, CHU de Rennes, Rennes, France, ¹³Department of Internal Medicine, Pitié-Salpêtrière Hospital, Paris, France, ¹⁴Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, ¹⁵Internal medicine, Hôpital des XV-XX, Paris, France, ¹⁶CHU Lille, Lille, France, ¹⁷Internal Medicine, Hospital J. Verdier, Bondy, France, ¹⁸Rheumatology, Fondation Rothschild, Paris, France, ¹⁹Rheumatology, Hôpital de Hautepierre, Strasbourg, France, ²⁰CHU Nice, Nice, France, ²¹Department de Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, AP-PH, UPMC, Paris, France, ²²Hôpital Jean Verdier, Bondy, France, ²³CHU Purpan, Toulouse, France, ²⁴CHU Bichat, Paris, France, ²⁵Internal Medicine, Hopital de Colmar, Colmar, France, ²⁶Ophtalmology, CHU de Rouen, Rouen, France, ²⁷Internal Medicine, Bichat-Claude Bernard Hospital, University Paris-7, Paris, France, ²⁸Ophtalmology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpétrière, Paris, France, ²⁹Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ³⁰biostatistics Saint Louis Hospital, paris, France, ³¹Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France
Background/Purpose: Anti-tumour necrosis factor (TNF) molecules have become a valuable addition to the therapeutic armamentarium for patients with severe uveitis. However, direct comparison of safety…
Abstract Number: 2038 • 2015 ACR/ARHP Annual Meeting
Adalimumab in Patients with Active, Noninfectious Uveitis Using High-Dose Corticosteroids
Antoine P. Brezin¹, Phillippe Kestelyn², Joachim Van Calster³, Glenn J. Jaffe⁴, Jennifer E. Thorne⁵, David Scales⁶, Pablo Franco⁷, Andrew D. Dick^8,9,10, Quan Dong Nguyen¹¹, Eric B. Suhler^12,13, Anne Camez¹⁴, Alexandra P. Song¹⁵, Martina Kron¹⁴, Samir Tari¹⁵, James T. Rosenbaum^16,17 and Arnd Heiligenhaus¹⁸, ¹Université Paris Descartes, Hôpital Cochin, Paris, France, ²Ghent University Hospital, Ghent, Belgium, ³University Hospitals Leuven, Leuven, Belgium, ⁴Duke University, Durham, NC, ⁵Johns Hopkins Medical Institute, Baltimore, MD, ⁶University of Texas Health Science Center, San Antonio, TX, ⁷Organización Médica de Investigación (OMI), Buenos Aires, Argentina, ⁸National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital, London, United Kingdom, ⁹University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom, ¹⁰University College London, Institute of Ophthalmology, London, United Kingdom, ¹¹Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, ¹²VA Portland Health Care System, Portland, OR, ¹³Casey Eye Institute, Oregon Health & Science Univ, Portland, OR, ¹⁴Abbvie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ¹⁵AbbVie Inc., North Chicago, IL, ¹⁶Devers Eye Institute, Legacy Hospital system, Portland, OR, ¹⁷Casey Eye Institute, Oregon Health & Science University, Portland, OR, ¹⁸Department of Ophthalmology at St. Franziskus Hospital Muenster, University of Duisberg-Essen, Muenster, Germany
Background/Purpose: Corticosteroids, currently the mainstay of uveitis treatment, are associated with adverse events and are not always fully effective. Multiple reports describe the use of…
Abstract Number: 2039 • 2015 ACR/ARHP Annual Meeting
Effect of Adalimumab on Visual Functioning (VFQ-25) in Visual-1 Trial Patients with Non-Anterior Non-Infectious Uveitis
John Sheppard¹, Avani D. Joshi², Manish Mittal², Keith Betts³, Samir Tari², Yanjun Bao² and Andrew D Dick⁴, ¹Virginia Eye Consultants and Eastern Virginia Medical School, Norfolk, VA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴University of Bristol, Bristol Eye Hospital, Bristol, United Kingdom
Background/Purpose: To compare the effects of adalimumab and placebo on the National Eye Institute Visual Functioning Questionnaire 25 (VFQ-25) in subjects requiring high dose corticosteroids…
Abstract Number: 2054 • 2015 ACR/ARHP Annual Meeting
Randomized, Double-Blind, Phase 3 Study of Efficacy and Safety of ABP 501 Compared with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
Stanley B. Cohen¹, Mark C. Genovese², Ernest H. Choy³, Fernando Perez-Ruiz⁴, Jose L. Pablos⁵, Nan Zhang⁶ and Primal Kaur⁷, ¹Metroplex Clinical Research Center, Dallas, TX, ²Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ³Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ⁴Servicio de Reumatología, Vizcaya, Spain, ⁵Instituto de Investigacion Hospital, Madrid, Spain, ⁶Biosimilars, Amgen, Inc., Thousand Oaks, CA, ⁷Amgen, Inc., Thousand Oaks, CA
Background/Purpose: ABP 501 is being developed as a biosimilar candidate to adalimumab (Humira®), a fully human recombinant monoclonal antibody. Evidence from analytical comparisons indicates that…
Abstract Number: 2059 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitor Tapering Induced Radiographic Progression Is Driven By Weighted Mean Disease Activity over Time, Not Flaring or Lower TNFi Exposition
Alfons A. den Broeder¹, Chantal A.M. Bouman¹, Aatke van der Maas², Frank H.J. van den Hoogen¹, Noortje van Herwaarden¹ and R. Landewe³, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Hengstdal 3, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Maastricht, Netherlands
Background/Purpose: DRESS, a randomized controlled strategy trial (RCT)1investigating disease activity guided tapering of etanercept and adalimumab compared to usual care in RA patients, indicated that…
Abstract Number: 2431 • 2015 ACR/ARHP Annual Meeting
Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis
Daniel Lovell¹, Nicolino Ruperto², Daniel J. Kingsbury¹, Rubén Burgos-Vargas², Tomoyuki Imagawa³, G Horneff², Pierre Quartier⁴, Steven Goodman¹, Andreas Reiff¹, Edward H. Giannini¹, Anabela Cardoso⁵, Jaclyn K. Anderson⁶, Nupun A. Varothai⁶, Jasmina Kalabic⁶ and Alberto Martini², ¹PRCSG, Cincinnati, OH, ²PRINTO, IRCCS G. Gaslini, Genova, Italy, ³Kanagawa Children’s Medical Center, Yokohama City, Japan, ⁴Hopital Necker-Enfants Malades, Paris, France, ⁵AbbVie, Amadora, Portugal, ⁶AbbVie, North Chicago, IL
Background/Purpose: The long-term safety of anti-tumor necrosis factor (TNF) drugs is particularly important in pediatric patients (pts) who may require prolonged treatment of their inflammatory…
Abstract Number: 1531 • 2014 ACR/ARHP Annual Meeting
CUT-Off LEVEL of Adalimumab and Prevalence of Antibodies ANTI-Adalimumab in Patients with Ankylosing Spondylitis: Results from a LOCAL Registry
Jose Rosas¹, Francisca Llinares-Tello², José M. Senabre-Gallego³, Carlos Santos-Ramirez⁴, Esteban Salas-Heredia³, Xavier Barber⁵, Gregorio Santos-Soler³, Juan Molina², Mario García-Carrasco⁶, Ana Pons³, Catalina Cano³ and Group Aire-MB³, ¹Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ⁴Rheumatology, Hospital Marina Salud, Denia, Spain, ⁵Universidad Miguel Hernández, CIO, Elche, Spain, ⁶Inmunología y Reumatología, Universidad Autónoma de Puebla, Puebla, Mexico
Background/Purpose To evaluate the Cut-off level of adalimumab (ADL) and the prevalence of antibodies anti-adalimumab (anti-ADL-ab), in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS).…
Abstract Number: 273 • 2014 ACR/ARHP Annual Meeting
Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis
Hermine Brunner¹, Nicola Ruperto², Carol A. Wallace³, Mary Toth⁴, Ivan Foeldvari⁵, John Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Pavla Vavrincova⁹, Daniel J. Kingsbury¹⁰, Katherine Marzan¹¹, Pierre Quartier¹², Kirsten Minden¹³, Elizabeth Chalom¹, Gerd Horneff¹⁴, Rolf M. Kuester¹⁵, Jason Dare¹⁶, Mareike Bereswill¹⁷, Hartmut Kupper¹⁷, Jasmina Kalabic¹⁷, Daniel Lovell¹⁸ and Alberto Martini¹⁹, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO, Genoa, Italy, ³University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ⁴Akron Children's Hospital, Akron, OH, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶University of Utah, Department of Pediatrics, Salt Lake City, UT, ⁷Pediatrics, Division of Pediatric Rheumatology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NC, ⁹Fakultni nemocnice v Motole, Praha, Czech Republic, ¹⁰Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹¹Children's Hospital Los Angeles, Los Angeles, CA, ¹²Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ¹³Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ¹⁵Asklepios Rheumazentrum Hamburg, Hamburg, Germany, ¹⁶Arkansas Children’s Hospital, Little Rock, AR, ¹⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁸Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ¹⁹PRINTO-IRCCS, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood. Adalimumab (ADA) is approved for moderate to severe polyarticular JIA…
Abstract Number: 1536 • 2014 ACR/ARHP Annual Meeting
Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Isabelle Fortin³, Boulos Haraoui¹, Jean Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard⁴, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: The order of use of biologic agents is still a question for debate. Phase III trial data in MTX-IR patients show comparable efficacy results…
Abstract Number: 102 • 2014 ACR/ARHP Annual Meeting
Real-World Utilization, Patient Characteristics and Persistency of Certolizumab Pegol Vs Other Anti-TNFs for the Treatment of Rheumatoid Arthritis in the United Kingdom
Frances Humby¹, Stephen Kelly¹, Angela V. Bedenbaugh², Nawab Qizilbash^3,4, Jochen Dunkel⁵, Belén SanJose³, Ignacio Mendez³, Jennifer Timoshanko⁶ and Jeyanesh Tambiah², ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ²UCB Pharma, Smyrna, GA, ³OXON Epidemiology, London, United Kingdom, ⁴Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom, ⁵UCB Pharma, Monheim, Germany, ⁶UCB Pharma, Slough, United Kingdom
Background/Purpose Several anti-TNFs are currently approved in Europe for RA treatment including certolizumab pegol (CZP), adalimumab (ADA), etanercept (ETN), golimumab and infliximab. UK NICE guidance…
Abstract Number: 1504 • 2014 ACR/ARHP Annual Meeting
Pharmacokinetic Equivalence of ABP 501 Relative to Adalimumab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects
Primal P. Kaur¹, Vincent Chow², Nan Zhang³, Mike Moxness⁴ and Richard Markus³, ¹Amgen, Inc., Thousand Oaks, CA, ²Pharmacokinetics and Drug Metabolism, Amgen, Inc., Seattle, WA, ³Biosimilars, Amgen, Inc., Thousand Oaks, CA, ⁴Clinical Immunology and BSM, Amgen, Inc., Thousand Oaks, CA
Background/Purpose Adalimumab is a recombinant IgG1 monoclonal antibody that binds to TNFα blocking its interaction with p55 and p75 cell surface receptors. ABP 501 is…

« Previous Page
1
…
8
9
10
11
12
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].